The study underscores the potential of targeting SLC16A1-AS1 in therapeutic strategies, where manipulating its expression could promote ferroptosis in cancer cells, offering a novel approach to treat renal cell carcinoma. Here, SLC16A1 is linked to hereditary clear cell renal cell carcinoma.